ArticleJournal of neurological surgery reports2026
Vestibular Dysfunction as a Novel Presentation of Middle Ear Neuroendocrine Tumor.
Article in Journal of neurological surgery reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to contribute to the sparse literature on middle ear neuroendocrine tumors (MeNETs) by detailing a unique case of MeNET-associated cochlear-vestibular dysfunction and outlining diagnostic, therapeutic, and follow-up considerations. Design: A single-patient case report. Setting: A tertiary academic referral center. Participant: A 40-year-old male presenting with profound left sensorineural hearing loss (SNHL), left vestibular hypofunction, and a middle ear mass. Main Outcome Measures: Histopathologic confirmation of MeNET, radiological identification of residual disease, postoperative symptom progression, and rehabilitation outcome. Results: Clinical evaluation, imaging, and histopathology confirmed the diagnosis of MeNET. Immunohistochemistry revealed positivity for chromogranin, synaptophysin, insulinoma-associated protein 1 (INSM1), cytokeratin mouse monoclonal antibody (CAM 5.2). An endoscopic middle ear exploration with tympanoplasty and canalplasty was performed, followed by vestibular rehabilitation. Surveillance with DOTA-Tyr3-octreotate PET/MRI identified residual disease, leading to a revision mastoidectomy. The patient experienced persistent imbalance postoperatively, requiring vestibular rehabilitation, and profound SNHL, for which a hearing aid evaluation was recommended. Conclusions: This case represents the first report of MeNET-associated cochlear-vestibular dysfunction. The significance of this report lies in the unique clinical presentation, the role of advanced imaging for surveillance, and the need for revision mastoidectomy following an initial endoscopic approach. This report discusses the challenges in achieving complete tumor clearance and emphasizes the need for continued case documentation and research into adjunctive therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.